全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Yu-Peng Zhou, PhD, Professor and Principal investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Zhongshan Institute for Drug Discovery. Dr. Zhou earned his bachelor's degree in chemistry in 2012 and master's degree in inorganic chemistry in 2014 from Sun Yat-sen University in China. He then pursued his PhD in chemistry at Technische Universit?t Berlin in Germany and obtained his PhD degree in 2018. Then Dr. Zhou moved to United States and joined the Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) as a research fellow. Dr. Zhou was promoted to instructor in 2023 at MGH/HMS. Since March 2024, Dr. Zhou has worked at Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Zhongshan Institute for Drug Discovery. Dr. Zhou’s research interests include organometallic chemistry, radiopharmaceutical, and PET imaging. Dr. Zhou’s research in US was funded by NIH-K99 grant and MGH. Dr. Zhou received the MGH Medical Discovery Award in 2020 and National Institutes of Health Pathway to Independence Award (K99) in 2022.

1.Development of new radiopharmaceutical

2.Development of new molecular imaging tools for CNS diseases

We have developed the first generation of small molecule Ca²⁺ channel α2δ-1 subunit PET tracer, [¹⁸F]tGBP4F and [¹⁸F]cGBP4F, for neuropathic pain imaging. We have also co-developed [¹¹C]3MeO4AP, a K⁺ channel PET tracer for MS, and led its radiation dosimetry evaluation (now preparing the IND and IRB application). We have contributed to building the [¹¹C]CHF₃ radiosynthesis system at PET center of Massachusetts General Hospital. We have developed a series of novel low-valent silicon compound and studied their applications in homogeneous catalysis. Our contributions to the field are highlighted by the co-authorship of 20+ peer-reviewed papers (including Angew. Chem. Int. Ed.、Eur. J. Med. Chem.、ACS Chem. Neurosci.), 1 book chapter, 1 patent application, and 5 oral presentations in international conferences.

1.Y. P. Zhou#, M.Q. Wilks#, M. Dhaynaut, N.J. Guehl, S.H. Moon, G. El Fakhri, M.D. Normandin* and P. Brugarolas*. Radiosynthesis automation, non-human primate biodistribution and dosimetry of K? channel tracer [11C]3MeO4AP. EJNMMI Research, accepted
2.Y. P. Zhou#, M. D. Normandin#, V. Belov, M. T. Macdonald-Soccorso, S. H. Moon, Y. Sun, G. El Fakhri, M., N. J. Guehl*, P. Brugarolas*, Evaluation of trans- and cis-4-[18F]Fluorogabapentin for Brain PET Imaging. ACS Chem. Neurosci. 2023, 14, 4208–4215.
3.Y. P. Zhou, Y. Sun, K. Takahashi, V. Belov, N. Andrews, C. J. Woolf, P. Brugarolas*, Development of a PET radioligand for α2δ-1 subunit of calcium channels for imaging neuropathic pain, Eur. J. Med. Chem. 2022, 242, 114688.
4.N. J. Guehl#, R. Neelamegam#, Y. P. Zhou#, S. H. Moon, M. Dhaynaut, G. El Fakhri, M. D. Normandin*, P. Brugarolas*, Radiochemical Synthesis and Evaluation in Non-Human Primates of 3-[11C]methoxy-4-aminopyridine: A Novel PET Tracer for Imaging Potassium Channels in the CNS. ACS Chem. Neurosci. 2021, 12, 756-765.
5.Y. P. Zhou, M. Driess*, Isolable Silylene Ligands Can Boost Efficiencies and Selectivities in Metal-Mediated Catalysis, Angew. Chem. Int. Ed. 2019, 58, 3715-3728.
6.Y. P. Zhou, M. Karni, S. Yao, Y. Apeloig*, M. Driess*, A Bis(silylenyl)pyridine Zero-Valent Germanium Complex and Its Remarkable Reactivity, Angew. Chem. Int. Ed. 2016, 55, 15096-15099.
7.Y. P. Zhou#, S. Raoufmoghaddam#, T. Szilvási, M. Driess*, A Bis(silylene)-Substituted ortho-Carborane as a Superior Ligand in the Nickel-Catalyzed Amination of Arenes, Angew. Chem. Int. Ed. 2016, 55, 12868-12872.